Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Phase 2 clinical trial data published in the New England Journal of Medicine (Jastreboff et al., 2023) demonstrated mean body weight reductions of up to approximately 24% over 48 weeks in adults with obesity a notable finding, though long-term durability data and head-to-head comparisons with other treatments are not yet available
These include orlistat, liraglutide, and semaglutide (NICE TA875 for weight management in adults with obesity), as well as GLP-1 receptor agonists within the framework of NICE NG28 (type 2 diabetes management)
- People with significant liver disease (the 9-month monkey toxicology study showed dose-dependent periportal vacuolation in hepatocytes that the FDA flagged as a possible safety signal)
Peptides like BPC-157 are being studied for their role in tissue repair, reducing inflammation, and supporting immune function
As with all prescription therapies, any decision is individual, formally assessed, and made only through proper medical channels
The timing strategy isn't about preventing pharmaceutical interaction
